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A new  delivery  method  via  polymeric  implants  was  used  for  continuous  exposure  to  PCBs.
Female Sprague-Dawley  rats  received  subcutaneous  polymeric  implants  containing  PCB126
(0.15% load),  PCB153  (5%  load),  or both,  for  up  to 45  d and  release  kinetics  and  tissue  distri-
bution  were  measured.  PCB153  tissue  levels on day  15  were  readily  detected  in lung,  liver,
mammary  and  serum,  with  highest  levels  in the  mammary  tissue.  PCB126  was  detected
only  in  liver and  mammary  tissues.  However,  a  completely  different  pharmacokinetics  was
observed  on  co-exposure  of PCB153  and  PCB126,  with a 1.8-fold  higher  levels  of  PCB153  in
the  liver  whereas  a 1.7-fold  lower  levels  in  the  mammary  tissue.  PCB126  and PCB153  caused
an increase  in  expression  of  key  PCB-inducible  enzymes,  CYP  1A1/2  and  2B1/2,  respectively.
Serum  and  liver  activities  of the  antioxidant  enzymes,  PON1  and  PON3,  and  AhR  transcrip-
tion  were also  signiﬁcantly  increased  by PCB126. 32P-postlabeling  for polar  and  lipophilic
DNA-adducts  showed  signiﬁcant  quantitative  differences:  PCB126  increased  8-oxodG,  an
oxidative DNA  lesion,  in  liver  and  lung  tissues.  Adduct  levels  in the liver  remained  upre-
gulated  up to 45  d,  while  some  lung  DNA  adducts  declined.  This  is  the  ﬁrst  demonstrationParaoxonase 1 (PON1) that  continuous  low-dose  exposure  to PCBs  via  implants  can produce  sustained  tissue  lev-
els leading  to the  accumulation  of  DNA-adducts  in  target  tissue  and  induction  of  indicator
enzymes.  Collectively,  these  data  demonstrate  that this  exposure  model  is  a promising  tool
for long-term  exposure  st
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1. Introduction
Polychlorinated biphenyls (PCBs), a group of chemicals
with 209 individual congeners, are persistent organic pol-
lutants  as reﬂected in their ubiquitous prevalence in the
environment and lipid solubility [1]. Intentional commer-
cial  production of PCBs in the US ceased before 1980, but
PCBs  remain as minor by-products of dye and paint man-
ufacture [2], and PCBs are still in use in closed systems,
This is an open access article under the CC BY license
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ike some transformers, which, according to the Stock-
olm Convention, are scheduled to be removed by 2025.
umans continue to be exposed to low doses of PCBs
ecause of their presence in the environment, their accu-
ulation in the food chain, and accidental release from
isposal sites [3]. Despite the gradual decline, PCBs remain
 major contaminant in human tissues [4,5]. Exposure to
CBs  in humans results in gastrointestinal effects, respira-
ory  tract symptoms, mild liver toxicity, and effects on the
kin  and eyes such as chloracne, altered pigmentation, and
ye  irritation. Other potential adverse health effects of PCBs
uch  as immunological disturbances, neurological defects
nd  implications in cardiovascular and liver diseases have
een  described [6,7]. The IARC recently concluded that
here  is sufﬁcient evidence of a link between PCBs and
elanoma, and limited evidence for PCBs and non-Hodgkin
ymphoma and breast cancer sufﬁcient to upgrade the
ntire  class of compounds to Group 1 Human Carcinogens
1,8]. Several studies have reported an increase in liver can-
er  among persons occupationally exposed to some PCB
ormulations [9].
The  PCBs’ carcinogenicity is clear in animal models.
sing Sprague-Dawley male and female rats, a comprehen-
ive chronic toxicity and carcinogenicity study analyzed
he  effects of four different commercial PCB mixtures
Aroclor 1016, 1242, 1254, and 1260) at multiple dietary
oncentrations, ranging from 25 to 200 ppm, during 24
onth  exposure [10]. They demonstrated more severe liver
oxicity  in females than in males and also found incidence
f  hepatocellular neoplasms was highly sex-dependent.
ikewise, chronic carcinogenicity studies with individual
CB  congeners, PCB118 (2,3′,4,4′,5-pentachlorobiphenyl)
nd PCB126 (3,3′,4,4′,5-pentachlorobiphenyl) found clear
vidence  of carcinogenicity in female Sprague-Dawley rats
11].
Most  of the rodent models of chemical carcinogenesis
nvolve exposure to the test compound either via gavage,
ntraperitoneal injection, or diet. The bolus doses used are
ften  orders of magnitude higher than the typical continu-
us  environmental exposure through ingestion, inhalation
nd  dermal uptake. These current animal exposure mod-
ls  are good for tumorigenesis studies to understand the
inetics  of carcinogen uptake, distribution, metabolism,
nd elimination. They also provide great insights into the
echanism of action of carcinogens. However, the condi-
ions  do not mimic  the human scenario where the exposure
s  generally to low doses for very long period of time. More-
ver,  application of highly toxic compounds via diet or
avage  may  put human animal handlers at risk of exposure
o  these compounds and are very stressful for the ani-
als.  We  hypothesize that continuous exposure to PCB126
nd  PCB153 (Fig. 1A) via novel subcutaneous polymeric
mplants, which provide controlled release for long dura-
ion,  will provide a more natural and environmentally safe
ay  of exposure which will lead to sustained overexpress-
on of different enzymes and a steady accumulation of
NA  damage that can potentiate PCB-induced liver and
ung  toxicities. PCB126 and PCB153 were selected because
f  their different mode of actions. PCB 126, a known
hR agonist and CYP1A1 inducer, is the most toxic PCB
ongener and has anti-estrogenic properties. PCB153 is ats 1 (2014) 820–833 821
diortho-substituted congener with CYP2B1 inducing prop-
erties  and is one of the most highly concentrated congeners
found in human tissues [12]. Moreover, in a study con-
ducted by National Toxicology Program, there was clear
evidence of carcinogenic activity of a binary mixture of
PCB126  and PCB153 in female Sprague-Dawley rats [13].
The  objectives of this study were 3-fold: (i) to correlate
the release kinetics of PCB126 and PCB153 from polymeric
implants in vitro and in vivo, as well as investigate tissue
distribution; (ii) to determine if co-exposure to PCB126 and
PCB153,  which have distinct modes of action, could change
the  pharmacokinetic proﬁles in rats and affect the DNA
damage accumulation; and (iii) to investigate the effects of
continuous  exposure to PCB on two  target tissues, liver and
lung,  as a hypothesis-testing tool for deriving mechanistic
insights for the observed results.
2. Materials and methods
2.1.  Chemicals
PCB126 (3,3′,4,4′,5-pentachlorobiphenyl) and PCB153
(2,2′,4,4′,5,5′-hexachlorobiphenyl) were synthesized
and characterized as described previously [14,15]. -
Polycaprolactone (PCL) mol. wt. 80,000 (P-80) was
purchased from Sigma–Aldrich (St. Louis, MO,  USA).
Pluronic F68 (F68) was  a gift from BASF Corp. (Florham
Park, NJ, USA). Silastic tubing was  purchased from Allied
Biomedical (Ventura, CA, USA). Bovine calf serum was from
Hyclone  (Logan, UT, USA). Dichloromethane (DCM), abso-
lute  ethanol and acetonitrile were from BDH chemicals
(VWR, West Chester, PA), Pharmco-AAPER (Louisville, KY,
USA)  and Sigma–Aldrich (St. Louis, MO,  USA), respectively.
Materials used in the 32P-postlabeling assay for DNA
adduct analysis were as described [16]. All other chemicals
were of analytical grade. All solvents used for the PCB
analysis were pesticide grade and obtained from Fisher
Scientiﬁc (Pittsburg, PA, USA). All analytical PCB standards
were purchased from AccuStandard, New Haven, CT, USA.
2.2.  Preparation of polymeric implants
Polymeric implants were prepared as described previ-
ously [19]. Brieﬂy, ﬁrst, we prepared polycaprolactone:F68
(PCL:F68) blank implants (1.2 mm dia) by extrusion
method [17,18]. These blank implants were then coated
with  20–25 layers of 10% of PCL dissolved in DCM con-
taining 0.15% and 5.0% PCB126 and PCB153, respectively.
The weight of the implant coatings was  60 mg  each thus
containing 90 g PCB126 or 3 mg  PCB153, respectively. The
coatings  were achieved by dipping the blank implants with
intermittent drying [19]. Sham implants were prepared in
the  absence of PCB. The implants were dried overnight and
stored  under argon until use.
2.3. Determination of in vitro release of PCBsThe release of PCB153 was measured as described
for other compounds [19]. Brieﬂy, implants (n = 3) were
separately placed in 20 ml  amber vials containing 10 ml
phosphate buffered saline (PBS) and 10% bovine serum.
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Fig. 1. Release of PCB126 and PCB153 from polymeric implants in vitro and in vivo. (A) Structures and polymeric implants of PCB126 and PCB153. (B) Daily
and  cumulative release of PCB153 from polymeric implants in vitro. (C and D) Cumulative release of PCB126 (C) and PCB153 (D) from polymeric implants
(one  1.5 cm × 2.6 mm  dia; 0.15 and 5% loads, respectively) grafted subcutaneously into female S/D rats. Animals were euthanized after 6, 15 and 45 d;
 spectro
CB126 arecovered  implants were solvent extracted to measure the residual PCBs
three  implants ± SD. Average daily dose over 45 d: 0.98 and 48.6 g of P
release.  **p < 0.01, ***p < 0.001.
The vials were incubated at 37 ◦C with constant agita-
tion in a water bath (Julabo SW 23, Seelback, Germany).
The medium was changed every 24 h. Media containing
PCB153 were extracted using acetonitrile and chloroform.
The release was measured spectrophotometrically and the
concentration was calculated against the standard curve.
The  absorbance was measured directly at 209 nm.  A cal-
ibration  curve of PCB153 was generated by spiking PBS
containing 10% bovine serum and 10% ethanol with known
concentrations of the test PCB. Since the amount of PCB126
in  each implant was very small, they were not assayed for
PCB  release in vitro.
2.4.  Animal study
Five-  to 6-week-old female Sprague-Dawley (S/D) rats
were  purchased from Harlan Laboratories (Indianapo-
lis, IN). All procedures were conducted after obtaining
approval from the Institutional Animal Care and Use Com-
mittee  (IACUC) and animals were maintained according
to  the IACUC guidelines. Animals were housed in cages
and  received 7001 Teklad 4% diet and water ad libitum.
The diet was purchased as pellets from Harlan–Teklad, Inc.
(Madison, WI)  and stored at 4 ◦C till use. After a week
of acclimation, animals were randomized into six groupsphotometrically against a standard curve; data represent an average of
nd PCB153, respectively. Release at 15 and 45 d was compared with 6 d
(n  = 4). Under anesthesia sham or PCB implants, one per ani-
mal,  were grafted into the subcutaneous cavity on the back
of  the animals and closed using a sterile 9-mm clip. Body
weight and diet consumption were recorded twice a week.
Four  groups were euthanized after 15 d of treatment, addi-
tional  two  groups were euthanized after 6 and 45 d. Rats
were  euthanized by CO2 asphyxiation, blood and tissues
were collected, snap frozen and stored at −80 ◦C until use.
Blood  was collected by cardiac puncture, plasma was sep-
arated  and stored at −80 ◦C. Implants were also recovered
from the animals, wiped, dried under vacuum and stored
at  −80 ◦C until analysis.
2.5.  Release of PCBs in vivo
Implants  (n = 3) collected from animals after 6, 15, and
45  d were analyzed for residual PCBs as described previ-
ously [19]. Brieﬂy, implants were dried overnight under
vacuum, weighed, and dissolved in 5 ml  DCM, followed
by the addition of 5 ml  ethanol to completely dissolve the
PCB.  The solution was  then diluted and analyzed using a
UV  spectrophotometer at 209 nm.  The cumulative release
from  the implant was calculated by subtracting the residual
amount from the initial amount. The daily release was  cal-
culated  by dividing the total release by time in days. Total
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CB released in vivo was compared with cumulative release
n  the same period in vitro.
.6. Tissue analysis for PCB126 and PCB153
Extraction and clean-up of PCBs from serum, lung,
iver and mammary tissue were performed after mixing
ith pre-extracted diatomaceous earth using a Dionex
SE  200 system (Dionex, Sunnyvale, CA) as described pre-
iously  [20]. 2,3,4,4′,5,6-Hexachlorobiphenyl was  added
o  all samples as a surrogate standard. The concentrated
xtract was subjected to a sulfur clean-up following a
ublished procedure [21]. PCB126 and PCB153 were quan-
iﬁed  with 2,2′,3,4,4′,5,6,6′-octachlorobiphenyl as internal
tandard using an Agilent 6890 N gas chromatograph with
63Ni -ECD detector equipped with a SPBTM-1 column
60 m × 0.25 mm × 0.250 m ﬁlm thickness; Supelco Ana-
ytical, Bellefonte, PA). The oven temperature program
as as follows: 100 ◦C, hold for 1 min, 5◦/min from 100
o  250 ◦C, hold for 20 min, 5◦/min to 280 ◦C, hold for
 min. Injector and detector temperatures were 280 ◦C and
00 ◦C, respectively, with a carrier gas (helium) ﬂow rate
f  1 ml/min. The detector response for PCB126 and PCB153
as  linear up to concentrations of 1.0 g/ml. The limit of
etection calculated from blank samples was 3.6 ng for
CB126  and 3.9 ng for PCB153. The recovery of the sur-
ogate  standard was 90 ± 11% (66–122%). The recoveries
f PCB126 and PCB153 from spiked blank samples were
4  ± 10% (67–100%) and 85 ± 9% (69–106%), respectively.
orrections were made for recoveries lower than 100%.
ammary tissue samples were pooled from four animals
or  the PCB analysis.
.7.  DNA isolation
DNA  was isolated from the liver and lung tissues by
 solvent extraction procedure [16] involving removal of
NA  and proteins by digestion of isolated crude nuclei
ith RNases (Sigma Chemical Co., St. Louis, MO) and
roteinase K (Roche Diagnostics, Indianapolis, IN), respec-
ively,  followed by sequential extractions with phenol
Amresco, Solon, OH), phenol:Sevag (1:1) and Sevag (cholo-
oform:isoamyl alcohol; 24:1) (Fisher Scientiﬁc, Pittsburgh,
A).  DNA was recovered by precipitation with ethanol,
ashed, dissolved in water and its concentration and purity
as  estimated by spectrophotometry.
.8.  Analysis of adducts
DNA  adduct proﬁles were determined by 32P-
ostlabeling/TLC systems [22] to assess DNA damage
omprised of polar adducts, including 8-oxodG and
ipophilic adducts. Brieﬂy, following enzymatic digestion
f  DNA (15–20 g), adducts were enriched by treatment
ith nuclease P1 (Calbiochem, Gibbstown, NJ), 32P-labeled
nd  resolved by 2-D PEI-cellulose TLC by development
ith 1 M formic acid in the presence of increasing con-
entration of sodium phosphate (50–1000 mM)  (D1)
nd  isopropanol:4 M ammonium hydroxide, 1:1 (D2).
-OxodGp was enriched by PEI-cellulose TLC, 32P-labeled,
nd resolved by 2-directional TLC as described [23].ts 1 (2014) 820–833 823
Normal nucleotides were labeled in parallel with adducts
and  separated by 1-D PEI-cellulose TLC. Adduct and nor-
mal  nucleotide radioactivity was measured by a Packard
InstantImager. Adduct levels were calculated as relative
adduct labeling (RAL) and expressed as adducts per 109 or
106 nucleotides.
2.9. Measurement of liver and serum TBARS levels and
serum total antioxidant capacity
The level of thiobarbituric acid reactive substances
(TBARS), expressed in terms of malondialdehyde, was
used  as index of liver and serum lipid peroxidation and
performed according to the methods described previ-
ously [24,25]. Brieﬂy, liver homogenate or the serum
lipid fraction was incubated with 0.8% or 0.67%, respec-
tively of thiobarbituric acid at 95 ◦C for 60 min  and the
red  pigment produced in the reaction was extracted
using a n-butanol–pyridine mixture (liver homogenate)
or n-butanol (serum). The pigment concentration was
determined spectrophotometrically at 535 nm for liver
samples and spectroﬂuorometrically at excitation 515 nm
and  emission 553 nm for serum samples. The total serum
antioxidant capacity was  determined using the Ferric
Reducing Ability of Plasma (FRAP) assay [26]. This assay
measures the reduction of ferric-tripyridyltriazine to the
ferrous  form as putative index of antioxidant or reducing
potential in the sample. Aqueous solutions of known Fe2+
concentration were used for calibration and results were
expressed as mol/l Fe2+ equivalents.
2.10.  Measurement of liver and serum PON1 activity
Paraoxon and phenylacetate were used as two indi-
vidual substrates in PON1 activity measurements as
described [27]. Brieﬂy, the enzyme activities were deter-
mined  spectrophotometrically following the initial rate of
substrate  hydrolysis to p-nitrophenol (412 nm)  or phenol
(270  nm), respectively. The units of enzyme activity were
calculated from the molar extinction coefﬁcients, E412
(18,290 M−1 cm−1) and E270 (1310 M−1 cm−1), respec-
tively, and expressed as U/ml serum or U/mg protein in
liver  homogenate.
2.11. Total RNA extraction
Total  RNA from tissue samples was isolated using an
RNeasy Mini KitTm following the manufacturer’s instruc-
tions.  An on-column DNase digestion was performed to
further  remove residue genomic DNA contaminants. The
quantity  and quality of RNA was  determined by the
absorbance at 260 nm (A260) and ratio between A260 and
A280  in 10 mM Tris buffer at pH 7.0.
2.12. Quantitative real-time polymerase chain reaction
(qRT-PCR)For  each sample, 2.5 g total RNA was reverse-
transcribed into cDNA in a 25 l reaction volume using
the  High Capacity RT KitTm following the manufacturer’s
instructions. qPCR was  performed as described earlier [28]
gy Repo824 F. Aqil et al. / Toxicolo
in a 20-l reaction with 4 ng of cDNA template and 900 nM
primer  using a SYBR Green Master Mix  kit from Applied
Biosystems Inc. (Foster City, CA) according to the man-
ufacture’s protocol. The primers used were taken from
previous publications as indicated in supplementary mate-
rials  and synthesized by Integrated DNA Technologies
Inc. (Coralville, IA). The relative gene expression levels
were calculated using the relative standard curve method.
The  target gene expression levels were adjusted to the
house  keeping gene, ribosomal protein L13a (RPL13a). Final
results  are fold change derived by dividing the expression
level of each gene in the treatment groups by that in the
control group.
2.13.  Western blot analysis
Western-blot  analysis was carried out as described
[17]. Brieﬂy, microsomal proteins were resolved on a
10%  sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and transferred onto a PVDF membrane. After
blocking  with 5% non-fat dry milk in blocking solution,
the membrane was incubated with CYP1A1 (1:4000 dilu-
tion),  CYP1A2 (1:3000 dilution) (Santa Cruz Biotechnology,
Santa Cruz, CA) and CYP1B1 (1:1500 dilution) (Abcam,
Cambridge, MA)  antibody overnight at 4 ◦C. The mem-
brane was then incubated with the appropriate horseradish
peroxidase-conjugated secondary antibody (Cell Signaling
Technology, MA), and the immuno-reactive bands were
visualized using the Pierce chemiluminescent substrate kit
(Thermo  Scientiﬁc, Rockford, IL). To ensure equal protein
loading, each membrane was stripped and re-probed with
-actin  antibody (Sigma–Aldrich, St Louis, MO)  to normal-
ize  for differences in protein loading.
2.14. Statistics
Data for DNA adducts represent average ± SD of 3–5
replicates and statistical analyses were performed using
the  Student’s t-test. Data for gene expression, PON activ-
ity  and TBARS are presented as means ± SD with statistical
analysis performed by Student’s t-test. All calculations
were performed with GraphPad Prizm statistical software
(v.  4.03; La Jolla, CA). In each assay a p value of <0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Release of PCB126 and PCB153 from polymeric
implants in vitro
The  polymeric implants of PCB126 and PCB153 were
prepared by the coating method with a PCB load of
0.15% and 5%, respectively (Fig. 1A). When 1.5-cm PCB153
implants were shaken in PBS containing 10% serum to
simulate in vivo extracellular ﬂuid conditions, a gradual
release of PCB153 was observed. The PCB153 release varied
between 75 and 90 g/d for the ﬁrst 7 d reaching a cumu-
lative release of nearly 23% in the ﬁrst week (Fig. 1B). The
release  gradually declined subsequently, reaching a cumu-
lative  release of about 45% at the end of 3 weeks. Due to therts 1 (2014) 820–833
low  load of PCB126, we were unable to measure its in vitro
release  kinetics.
3.2.  In vivo release
The  in vivo releases of PCB126 and PCB153 were
assessed by measuring the residual PCBs in the implants
recovered from the animals at the time of euthanasia.
At the end of the 6, 15 and 45 d, PCB126 was released
from the polymeric implants by 26%, 36% and 49%, respec-
tively  (Fig. 1C). PCB153 was  released at nearly 50% higher
rates,  i.e., 40%, 53%, and 73%, respectively (Fig. 1D). These
data  show that both PCB126 and PCB153 continued to be
released  for more than 6 weeks, with over 25–50% of the
compound still present in the implants at the end of the
study.  No physical change to the polymeric implants or
any  sign of toxicity at the site of implantation in the ani-
mals  was  observed. A comparison of the in vitro and in vivo
release  kinetics suggest that almost twice as much PCB153
was  released from the implants in vivo compared with the
in  vitro release. Based on the release kinetics in vivo, the
average daily doses of PCB126 and PCB153 over 45 d of
treatment were 0.98 ± 0.10 and 48.6 ± 3.0 g, respectively.
3.3. Effect of the PCB126 and PCB153 exposure on the
body, organ and tissue weights
Average body weights of animals treated with PCB126
or  PCB153 for 15 d were not statistically different when
compared with sham-treated animals (Table 1). However,
a  slight reduction in body weight was  observed when
animals were treated with a combination of PCB126 and
PCB153  (169 ± 6 g vs. 179 ± 4 g). There was  no treatment-
related effect on food consumption (data not shown).
Compared to sham controls, liver weights of ani-
mals treated with PCB126 alone or in combination with
PCB153 increased signiﬁcantly (9.8 ± 0.1 g and 9.8 ± 0.8 g
vs.  7.4 ± 0.2 g, respectively). However, treatment with
PCB153 alone did not affect liver weights. The lung weights
were  non-signiﬁcantly elevated by treatment with PCB126
alone  or in combination with PCB153. In contrast, PCB126,
with  or without PCB153 co-exposure, caused a dose- and
time-dependent reduction in thymus weight. In fact, the
relative  thymus weight was  reduced by three quarters after
45  d treatment with a combination of PCB126 and PCB153
(Table 1). Some reduction in the weights of ovary and mam-
mary  tissues were also observed in these treatment groups
although not signiﬁcant. PCB153 alone did not inﬂuence the
lung  or thymus weights, but caused a small non-signiﬁcant
increase in the relative weights of ovary and mammary.
Kidney weights were essentially unaffected by any of the
PCB  treatments (Table 1).
3.4. Tissue distribution of PCBs
The levels of PCB126 and PCB153 were determined in
different tissues (lung, liver and mammary) and serum by
GC  analysis. No detectable levels of PCB126 were found
in  the serum and lung. However, PCB126 accumulated in
the  liver (860 ± 110 ng/g tissue) after 15 d of the PCB126
alone treatment (Table 2). The levels of PCB126 in the
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Table 1
Effect of PCB126 and PCB153 on the organ and tissue weight.
Group/implants Duration of
study  (d)
Body wt. (g) Liver (mg/g bw) Lung (mg/g
bw)
Kidney (g) Thymus (mg) Ovary (mg) Mammary (g)
Untreated control 15 179 ± 3.6 42.6 ± 1.2 6.0 ± 0.3 1.4 ± 0.1 359 ± 6 111 ± 9 3.1 ± 0.3
Sham Implants 15 178 ± 10.4 40.9 ± 0.8 6.4 ± 1.0 1.4 ± 0.1 323 ± 2 112 ± 16 3.5 ± 0.2
PCB153 15 181 ± 11.7 40.5 ± 3.5 5.8 ± 0.5 1.4 ± 0.1 358 ± 3 128 ± 17 3.8 ± 0.6
PCB126 15 177 ± 4.8 55.2 ± 4.4* 8.2 ± 2.4 1.3 ± 0.1 222 ± 3* 93 ± 16 2.9 ± 0.6
PCB126 + PCB153 6 156 ± 3.9 53.2 ± 4.4* 6.5 ± 0.5 1.3 ± 0.2 270 ± 3*** 80 ± 13 2.6 ± 0.2
PCB126 + PCB153 15 169 ± 5.9 57.9 ± 3.4* 7.7 ± 1.5 1.4 ± 0.2 248 ± 6*** 93 ± 14 3.0 ± 0.2
PCB126 + PCB153 45 213 ± 7.3 48.3 ± 2.5* 6.6 ± 0.4 1.5 ± 0.1 110 ± 1*** 105 ± 9 3.5 ± 0.7
Data shown is average ± SD of four animals.
* Signiﬁcantly different from the 15 d untreated control, p < 0.05.
*** Signiﬁcantly different from the 15 d untreated control, p < 0.001.
Table 2
PCB126 and 153 levels in serum, lung, liver and mammary tissue adjusted for serum or tissue wet weight.
Treatment group Levels (ng/g serum or tissue)
Serum Lung Liver Mammarya
PCB126 PCB153 PCB126 PCB153 PCB126 PCB153 PCB126 PCB153
Sham (15 d) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
PCB153 (15 d) n.d. 150 ± 20 n.d. 1600 ± 760 n.d. 930 ± 80 n.d. 7150
PCB126 (15 d) n.d. n.d. n.d. n.d. 860 ± 110 n.d. 120 n.d.
PCB126 + PCB153 (6 d) n.d. 170 ± 20 n.d. 1400 ± 160 780 ± 80 1350 ± 260 80 12,000
PCB126 + PCB153 (15 d) n.d. 220 ± 30 n.d. 1200 ± 290 1200 ± 160 1700 ± 310 110 4200
PCB126 + PCB153 (45 d) n.d. 170 ± 30 n.d. 850 ± 130 1000 ± 170 1350 ± 310 140 4600
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a Pooled samples from four animals were used for this analysis, therefor
etection  limit.
iver were somewhat higher when PCB126 was combined
ith PCB153 (1200 ± 160 ng/g). The liver PCB126 levels
ncreased from 6 d of treatment to 15 d but then remained
nchanged up to 45 d of treatment. Compared to the livers,
early  10-fold lower levels of PCB126 were detected in the
ammary  tissue (Table 2).
PCB153 was  readily detected in the serum and tissues
nalyzed since the dose of PCB153 administered was  about
0  times higher than that of PCB126. In serum PCB153 was
resent  at the level of 150 to 220 ng/g serum after exposure
o  PCB153 alone or in combination with PCB126 (Table 2).
ung  (850–1600 ng/g tissue) and liver (930–1700 ng/g tis-
ue)  showed similar levels of PCB153 accumulation and
he  levels were essentially sustained from 6 d to 45 d
f  the treatment. Liver levels were nearly doubled when
CB153 was given in combination with PCB126 (1700 ng/g
s  930 ng/g tissue with PCB153 alone). The maximum accu-
ulation  of PCB153 was found in the mammary tissues,
articularly at the early time point (12,000 ng/g on day
,  PCB153 + PCB126 treatment). After 15 d of exposure
CB153 treatment alone resulted in 7150 ng PCB153/g tis-
ue  while levels were much lower (4200 ng/g tissue) when
CB153  was combined with PCB126. The levels thereafter
emained unchanged (4600 ng/g tissue) until 45 d of the
reatment in this treatment group (Table 2).
.5. DNA adducts analysisDNA  adduct analysis was performed using the highly
ensitive 32P-postlabeling technique. A wide array of DNA
dducts, ranging from highly polar to highly lipophilic,
ere detected in the liver and lung of PCB126- andle value is provided without SD; n.d. = samples were below the respective
PCB153-treated animals. Based on the chromatographic
properties, the adducts were grouped into P-1, P-2, PL-
1,  and PL-2 subgroups, where P stands for polarity and
PL  is used to designate adducts that have both polar and
lipophilic properties based on requirement of salt con-
centration during the chromatography [29]. No qualitative
difference in adduct proﬁles among the various treat-
ment groups were observed (Fig. 2A). However, signiﬁcant
quantitative differences occurred for some subgroups of
adducts.
Time  and treatment effects on mean adduct levels of the
different adduct groups in liver tissue are depicted in Fig. 2B
and  Supplemental Figure 1A. Liver samples showed high
basal  levels of P-1 adducts (9485 adducts/109 N nucleotide)
that did not change with PCB153 and/or PCB126 treatments
(Fig.  2B). P1 adduct levels after 6 d of co-exposure were
almost identical to sham treatment and did not change
even after 45 d of treatment. The known oxidative lesion, 8-
oxodG,  which constitutes part of the P-2 subgroup, showed
signiﬁcant increases in DNA adducts by PCB126 treat-
ment. PCB153 also produced a modest but non-signiﬁcant
increase in adducts. Co-treatment produced a doubling in
8-oxo-dG  levels which remained below the level of signif-
icance  (Fig. 2B). The adduct levels did not change when
different time points were tested in co-treatment (Supple-
mentary Figure 1). Highly lipophilic PL-1 adducts increased
with  the treatment of PCB153 compared to sham, however,
the  increase was  not signiﬁcant. The increase in the adduct
levels  was similar with PCB126. Non-signiﬁcant increases
were  also seen in PL-2 adducts levels with either treat-
ment which seemed to be higher with PCB126 compared to
PCB153  and at the earlier time point with the co-treatment
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Sham PCB126
P-1
PL-1
PL-2
B: LiverA C: Lung
8-oxodG
*
32 lic DNA 32
6 or sha
ily doseFig. 2. P-postlabeling/TLC analysis of liver and lung polar and lipophi
tissue  on day 15 from female S/D rats after continuous exposure to PCB12
in  indicated tissues following 15 d of sham or PCB exposure; average da
represent  an average of four rats ± SD. *p < 0.05.
than at the later time point (Fig. 2B and Supplemental Fig-
ure  1A).
These different groups of adducts were also ana-
lyzed in the lungs of PCB-treated animals. Irrespective
of the adduct type, the baseline levels were almost 3-
fold  lower in the lung samples compared to liver (Fig. 2C
and  Supplemental Figure 1B). P1 adducts were almost
unchanged compared to sham by the treatment with either
PCB153  or PCB126 alone (2808 ± 682 vs. 2784 ± 1032 and
3006  ± 1037 adducts/109 N nucleotide, respectively). How-
ever,  adduct levels increased (4161 ± 1381 adducts/109 N)
when  PCB126 and PCB153 were co-administered. In the
co-treatment group, adduct levels peaked after 15 d and
remained essentially unaltered after 45 d (Supplemen-
tal Figure 1B). As seen for the liver samples, 8-oxodG
increased signiﬁcantly (p = 0.027) following treatment with
PCB126.  The adduct levels in co-treatment groups were adducts. (A) representative P-postlabeling DNA adduct maps of lung
m from subcutaneous polymeric implants. (B and C) DNA adducts levels
 over 15 d: 2.18 and 105.5 g of PCB126 and PCB153, respectively. Data
maximum after 6 d and decreased gradually as time of
treatment increased. There was  no difference in the PL-1
adduct  levels by any of the treatment (Fig. 2C) but the level
was  somewhat decreased with time in the co-treatment
group (Supplemental Figure 1B). Although in the liver PL-
2  adducts seemed increased in groups exposed to PCB126
either alone or in combination with PCB153, this effect was
not  signiﬁcant. Interestingly, the increased PL-2 adduct lev-
els  in co-treated groups remained the same even after 45
d  of treatment (Supplementary Figure 1B).
3.6. Liver and serum lipid peroxidation and serum
antioxidant capacityLiver  and serum TBARS levels, expressed in terms for
MDA,  and serum antioxidant capacity measured as the
ferric-reducing ability were measured in serum and liver
F. Aqil et al. / Toxicology Reports 1 (2014) 820–833 827
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ow  doses of PCB126, PCB153 or their combination via subcutaneous pol
he  data from the 15 d time point. Average daily dose of PCB126 and PCB1
f the various treatment groups. There was no effect of
ny  treatment on total serum antioxidant capacity (Sup-
lemental Figure 2). Similarly, PCB126 or PCB153 alone or
n  combination did not increase liver TBARS values (Fig. 3A).
o  signiﬁcant effect of PCBs on serum TBARS was observed
ither initially, although non-signiﬁcant increases after 15
nd  45 d exposure to PCB126 together with PCB153 were
isible  (Fig. 3B).
.7.  Effect of PCBs on serum and hepatic PON1 activities
Two substrates, paraoxon (paraoxonase activity) and
henylacetate (arylesterase activity) were used to mea-
ure  the PON1 activity in serum and liver tissues of the
arious treatment groups. PON1 activity in the hepatic tis-
ue  of control animals was about 2.4 and 4.8 U/mg protein
ith  paraoxon and phenylacetate substrate, respectively.
epatic levels for PON1 activity were unaffected by PCB153 of female S/D rats were analyzed following treatment with continuous
mplants for 6, 15 and 45 d. A(i), B(i) and sham group in A(ii), B(ii) show
given in Figs. 1 and 2 legends.
treatment. However, the PON1 activities increased 3–5-
fold  with PCB126 alone and in combination with PCB153
(Fig.  4A). This effect was  evident during the entire 45 d of
treatment.
Serum  PON1 paraoxonase and arylesterase activity in
sham  groups was  found to be 370 U/ml and 270 U/ml,
respectively, and remained unchanged following treat-
ment  with PCB153 (Fig. 4B). However, treatment with
PCB126 alone or in combination with PCB153 signiﬁcantly
increased the PON1 activity in serum. The effect was  even
more  pronounced with paraoxon as substrate.
3.8. Effect of PCBs on gene expression in liver tissueHepatic gene expression analysis of PON1, PON2, and
PON3  by qRT-PCR showed no difference in sham and
PCB153-treated animals. However, an almost 1.5-fold
increase in the mRNA levels of PON1 was  observed in
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their  combination for different times was determined with two  substrate
the  data from the 15 d time point. Data represented as mean ± SD (n = 4).
animals treated with PCB126 alone and in combination
with PCB153 groups (Fig. 5A). Similarly, PCB126 alone and
in  combination also increased the amount of PON3 mRNA
by  almost 2-fold (Fig. 5C). In contrast, PON2 and APOA1
mRNA expressions were unaffected by the PCB treatments
(Fig. 5B and E). A signiﬁcant increase in the mRNA levels of
AhR  was observed after exposure to PCB126 alone and in
combination with PCB153 (Fig. 5D).
Cytochrome P450 levels were determined by mRNA
analysis and also tested at protein level by western blot
analysis. As expected, CYP1A1 mRNA was upregulated very
substantially (>1000 fold) by PCB126 treatment (Fig. 6A). A
similar  effect was observed when PCB126 was co-delivered
with PCB153. This overexpression was sustained during
the  entire course of the treatment (up to 45 d). In these
treatment groups we also observed the same trend with
more  than 200-fold increases in CYP1A1 protein levels
and  similar increases in CYP1A2 and CYP1B1 protein levels
(Fig.  6C). CYP2B1/2 mRNA was elevated by PCB153 treat-
ment.  PCB126 did not alter the CYP2B1/2 mRNA expression
but  interestingly, a signiﬁcant increase of the PCB153-
induced levels of CYP2B1/2 gene transcription was  noted
after  co-exposure to PCB126 (Fig. 6B). The effect was max-
imal  after 6 d of exposure to PCB153 given in combination
with PCB126, but decreased gradually after 15 and 45 d of
treatment.sure. PON1 activities in tissues of rats treated with PCB126, PCB153 and
xon and phenylacetate. A(i), B(i) and the sham group in A(ii), B(ii) show
4.  Discussion
Dose response is a well-established phenomenon, but
studies almost always use bolus doses of test compounds
to determine their DNA-damaging and carcinogenic poten-
tial.  Such bolus doses, however, are far from the normal
scenario in which humans are generally exposed to very
low  doses of toxicants for long durations. The polymeric
implant-delivery system provides continuous (“24/7”)
exposure to low doses. To assess the effect of such con-
tinuous, low-dose exposure, PCBs were delivered via the
implant  route to rats. In published studies bolus doses were
administered by daily gavage (up to 3000 g PCB153 and
1  g PCB126/kg b. wt.  per d for up to 2 years) or multi-
ple injections (10–10,000 g/kg/d PCB153 in combination
with up to 10 g/kg/d PCB126, for 6 weeks) [13,30–33]. The
implant  delivery method used in this study slowly but con-
tinuously  released over 45 d an average daily dose of 49 g
PCB153  and 0.98 g/d PCB126, equivalent to a daily dose
of  about 200 g PCB153/kg and 5 g PCB126/kg (based
on 200 g rat) from a single polymeric implant. Thus, the
implants delivered comparable daily doses but at a con-
tinuous rate and without the need of daily handling of the
animals  for gavage or i.p. injections. This is less stressful for
the  animals and also lowers the risk of accidental human
contact with the toxic test compounds.
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evels  were determined by qRT-PCR and adjusted based on the level of the
oint.  Data represent means of four rats ± SD.
The organ weights were differentially affected depend-
ng  on the type of PCB used. Liver weights were signiﬁcantly
ncreased by PCB126 alone or in combination with PCB153
nd  a similar, non-signiﬁcant, effect was also observed in
ung  tissues. Elevated liver weight and reduction in thymus
eight  are well-known consequences of AhR-mediated in
ndoplasmic  reticulum [34], and PCB126 is the most potent
hR  agonist of all 209 PCB congeners.
The release is largely sustained in the coated polymeric
mplants used in this study [19]. The in vitro release of
CB153 from the coated polymeric implants was fairly con-
tant  during the ﬁrst 7–8 d and then it gradually declined
Fig. 1B) effects such as an increase. We  have previously
escribed that during in vivo release, extracellular ﬂuid
rom  the site of implantation enters into the polymeric
atrix, dissolving the compound that then diffuses out into
he  surrounding tissue [17,35]. In this study the average
n  vivo release of PCB153 was almost 1.6-fold higher than
he  average in vitro release over the ﬁrst 15 d. The higher
elease in rats presumably results from differences in ‘sink’
onditions where the large volume of circulating body ﬂuid
ay  cause higher releases [17].A1 (E) in the liver of rats exposed to PCBs via polymeric implants. mRNA
eeping gene rRPL13a. The sham group shows the data from the 15 d time
PCBs from implants are expected to enter into the sys-
temic circulation and to be distributed to different tissues.
In  this study, PCB153 accumulation in the liver and lung
was  similar at all time intervals, but much higher in mam-
mary  tissue (nearly 8-fold higher after 7 d, and about 2.5-
and  3-fold higher after 15 and 45 d, respectively), most
likely due to the very high fat content of mammary tissue
[36].  Even PCB126, which was below the detection limit in
the  lung and serum, was present at measurable amounts
in  mammary tissue. It is intriguing, however, that despite
the  50-fold higher average daily dose of PCB153 (48.6 g)
compared to PCB126 (0.98 g), these PCB congeners were
present at essentially the same levels in the liver during
the  entire course of the study. The higher hepatic accumu-
lation of PCB126 compared with PCB153 may  reﬂect their
respective binding sites in the liver. PCB126 levels were 10-
fold  higher in the liver than in mammary tissue, supporting
the  concept of hepatic sequestration of PCB126 found in
previous  studies with mice [37]. The protein responsible
for the hepatic sequestration of PCB126 has been shown
to  be CYP1A2, an AhR-inducible gene [37–40]. In con-
trast, PCB153 levels in mammary tissue on day 15 were
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the  rat liver after 15 d of treatment with indicated PCBs. Co-treatments s
the  data from the 15 d time point. *p < 0.05, ***p < 0.001.
lower when PCB126 was co-administered while liver lev-
els  were higher than in the PCB153 only group. To our
knowledge the mechanism of this increase in liver to fat
ratio  of the very lipophilic PCB153 during co-exposure with
AhR  agonists has not been elucidated. However, the role
of  induction of metabolism or the metabolic capabilities
cannot be completely ruled out. Studies on hepatic seques-
tration  of PCB153 with CYP1A2 knock-out and wild-type
mice did not show any difference in tissue levels, unlike
PCB126 which was higher in the liver of wild-type mice
only  [37].
Delivery of PCBs with the implant system resulted
in near steady-state DNA adduct accumulation for most
types  of adducts tested in this study, even after 6 weeks
of  exposure. This is consistent with steady DNA adduct
accumulation following long-term exposure of A/J mice to
cigarette  smoke [41] and multiple low-dose administration
of benzo[a]pyrene [18,42].
One type of adduct, the P-2 group which is mostly com-
posed of 8-oxo-dG, showed signiﬁcantly increased levels in
the  liver and lung of PCB126 alone-treated animals after 15
d  of exposure. Co-exposure to PCB126 and PCB153 resulted
in  an almost doubling of P-2 (8-oxodG) adducts in the
liver  and lung of treated animals compared to sham con-
trols  on day 6. Although this increase was not statisticallyt average of four rats ± SD. (C) protein levels of CYP1A1, 1A2 and 1B1 in
 time response at 6, 15, and 45 d (A and B only). The sham group shows
signiﬁcant, it was sustained over the whole treatment
period in the liver, while it decreased in the lung. To the
best  of our knowledge this is the ﬁrst report of signiﬁ-
cantly increased 8-oxodG levels in PCB126-exposed rats.
Other  types of adducts, particularly PL-1, seemed ele-
vated by PCB126 and PCB126 plus 153 treatment, but
none  reached statistical signiﬁcance. Similarly, other inves-
tigators  reported increased M1dG adducts in rat livers
co-exposed daily to 300 ng/kg PCB126 and 3000 g/kg
PCB153 for a year [31]. It is not clear how PCB126 and
other toxicants increase oxidative stress, but uncoupling of
idle  high levels of CYPs, changes in the metabolic pathway
of  endogenous compounds like estradiol leading to redox-
cycling  estradiol quinones, and others have been suggested
as  the possible mechanisms [43,44].
The elevated 8-oxo-dG levels suggest increased oxida-
tive  stress in the liver and lung of PCB-exposed rats.
However, we did not observe a signiﬁcant increase in
liver  and serum TBARS values. Total serum antioxidant
capacity was not signiﬁcantly reduced, although it was
higher  when serum TBARS was  lower and vice versa. One
antioxidant parameter in tissues and serum are paraox-
onases. PON1 prevents lipid peroxidation and we observed
a  signiﬁcant increase in the levels of PON1 activity in
serum and livers of animals exposed to PCB126 alone or
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n combination. Thus elevated PON1 may  have suppressed
ncreased oxidative damage to lipids as measured in TBARS
ithout  being equally efﬁcient in preventing oxidative
amage of DNA.
PON1,  a member of a three gene family which includes
ON2 and PON3, is the body’s ﬁrst line of defense against
xposure to certain toxicants like paraoxon [45,46]. Similar
o  published report [28], PCB126-treated groups showed
igniﬁcantly increased PON1 activities in serum and liv-
rs  while PCB153 failed to increase PON1 activity. The
CB126-induced increase in PON1 activity was sustained
nd  not time-dependent from day 6 to day 45, reﬂecting
he continuously sustained exposure to PCB126. Simi-
arly,  proteome analysis showed a large increase in serum
araoxonase/arylesterase levels in male mice livers after
xposure to PCB126, a high dose of PCB153, or a combina-
ion of the two PCBs [47].
To  analyze the cause of the increase in PON1 activity
nd to compare of effects of PCB126 and PCB153 on CYPs
ith  those on the members of the PON family and others,
e  measured PON1, PON2 and PON3, CYP1A1, CYP2B1/2,
hR and APOA1 mRNA levels in livers, and CYP1A1, 1A2
nd  1B1 protein levels in livers and lungs. PCB153, a CAR
gonist, only affected the expression of CYP2B, an effect
hat  was signiﬁcant only with coexposure to PCB126. This
s  consistent with our observation that co-exposure with
CB126  increased PCB153 accumulation in the livers, pos-
ibly  through a sequestration mechanism like the one
escribed for PCB126 and CYP1A2. This ﬁnding is also in
greement with the combined effect observed with PCB126
nd  PCB153 for cancer induction and M1dG adduct forma-
ion  [13,31] and our ﬁnding may  provide the explanation
or this combined effect, underscoring the need for more
ixture experiments to achieve realistic risk assessments.
PCB126 is the most potent AhR agonist among all
CB congeners tested [48]. Consistent with published
ata, CYP1A1 was nearly 1000-fold upregulated at all
ime-points and a large increase in CYP1A1/2 protein
as seen in the livers and also in the lungs of PCB126-
xposed rats. PON1 transcription was nearly doubled in
he  livers of all PCB126 groups. The PON1 gene pro-
oter has XRE-like sequences, suggesting AhR activation
f  PON1 transcription [49]. However, the mechanism and
he  ligand-speciﬁcity are not fully understood [50]. Sur-
risingly, PCB126 had an even stronger inducing effect on
ON3  transcription. PCB126 also signiﬁcantly increased the
RNA  level of the AhR in the liver. Sustained AhR activa-
ion  is believed to be the mechanism of the many negative
ealth effects of dioxin like compounds [51,52]. Implant
tudies with lower doses of PCB126 or other AhR agonists
ay  be a useful tool to further explore the long term con-
equences of low dose exposure to these compounds via
ood,  air or water and possible intervention strategies with
ntagonists like resveratrol.
In  summary, the use of polycaprolactone implants is
ell  established for the delivery of chemopreventives [19]
nd  contraceptives [53]. However, their use in the deliv-
ry  of persistent environmental pollutants like PCBs is
ovel.  Data presented in this manuscript are the ﬁrst
emonstrating steady accumulation of DNA adducts in
otential  target tissues, liver and lung, with continuousts 1 (2014) 820–833 831
exposure to PCB126. This study also demonstrates for the
ﬁrst  time that low-dose exposure to PCBs leads to sustained
overexpression of known CYP1A1/2, and new, PON1/3,
marker genes. Finally, these studies show that the com-
bined  genotoxicity and carcinogenicity of PCB126 with
PCB153 may  lie in the increased sequestration of PCB153
in  the target organs. Thus, polymeric implants provide an
efﬁcient,  low cost, and safe delivery mechanism to explore
the  carcinogenicity of compounds and mixtures that we
encounter in everyday life.
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